QuidelOrtho Corporation (QDEL)

Over the past six months, QuidelOrtho's stock price has declined significantly. Key events impacting the stock include the Q4 2025 earnings report, leadership and portfolio changes, a goodwill impairment charge, and analyst downgrades. In Q4 2025, adjusted diluted earnings per share beat estimates, and total revenue was $724 million. A director purchased shares, the CFO announced retirement, and the company expanded its immunoassay portfolio. The company recorded a $701 million non-cash goodwill impairment charge in Q3 2025. Wall Street Zen and Zacks Research downgraded QuidelOrtho's rating.

Demand for QuidelOrtho's respiratory products is affected by the seasonal demands of the respiratory season. In Q4 2025, respiratory revenue declined due to lower COVID-19 testing, while flu revenue grew. For the full year 2025, respiratory revenue declined due to lower COVID-19 testing, though flu revenue still grew. The company's constant currency revenue has averaged 3.8% year-on-year declines over the last two years.

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products, specializing in in vitro diagnostics. The company develops, manufactures, and markets rapid diagnostic testing solutions, immunoassay, molecular testing, clinical chemistry, and transfusion medicine products. Its products include tests for infectious diseases, cardiac and autoimmune biomarkers, and COVID-19. The company sells its products directly and through distributors to various end-users, including physician offices, hospitals, and laboratories.

QuidelOrtho Corporation has a global presence in North America, EMEA, China, Japan and Asia Pacific, and Latin America, with the majority of revenue from North America. Production plants are in the U.S. and the U.K., with sales offices, administrative buildings, and warehouses worldwide.

QuidelOrtho's brand reputation has been impacted by a class-action lawsuit alleging that the company misled investors regarding the demand for its products and undisclosed problems with the Savanna RVP4 Test, which led to the withdrawal of its FDA submission and a stock price drop. Despite these challenges, QuidelOrtho has also received positive recognition, including an Excellence Services Label in EMEA and two Stevie® Awards.

QuidelOrtho Corporation is predominantly owned by institutional investors, who collectively held around 112.15% of the company's shares as of March 2025. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Fmr Llc. Jack W. Schuler is the largest individual shareholder, owning 12.60% of the company. Insiders collectively owned 0.63% as of March 2025.